TORONTO, Ontario, April 28, 2022 – Takeda Canada Inc. is pleased to announce that Héma-Québec has awarded a two-year tender for TAKHZYRO® (lanadelumab injection) as the sole option for prophylaxis subcutaneous (SC) treatment for type I/II hereditary angioedema (HAE) patients. The two-year term which begins April 1, 2022, includes the option for Héma-Québec to extend… Read MoreEn savoir plus
HAEGARDA® is now available in the province of Québec
CSL Behring Canada For Immediate Release HAEGARDA® is now available in the province of Québec for the routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients OTTAWA, Canada, 5 February 2020. CSL Behring Canada announced that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), is now available in the province of Québec. HAEGARDA is a… Read MoreEn savoir plus
Educational Day 2018
Saturday September 29, 2018 – 9AM to 5PM Will be held a conference day to inform about hereditary angioedema The activity is open to anyone interested or interested in the subject (patients, caregivers, professionals and health managers, representatives of the pharmaceutical industry, etc.) The morning will be dedicated to scientific conferences while a workshop will… Read MoreEn savoir plus
CHOI Radio X (98.1) is proud to support
AOHQuebec CHOI Radio X (98.1) is proud to support AOHQuebec by announcing the launch of the association’s new website. For the occasion, two pairs of tickets for the Desjardins section of the Montreal Canadiens at Bell Center (unlimited food and soft drinks) will be drawn among the listeners of the Jeff Fillion show between 11:30… Read MoreEn savoir plus
Demystify hereditary angioedema
https://youtu.be/Or3FonZ5llI
The new official website of the AOHQuebec is launched!
Loading... Taking too long? Reload document | Open in new tab